Eyenovia to Participate in the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference
Eyenovia Inc. (NASDAQ: EYEN), an ophthalmic technology company, announced its participation in the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference on August 15th, 2024. The company's pre-recorded presentation will be available on-demand starting at 7:00 am EDT on the conference day.
Eyenovia is known for commercializing Mydcombi™, an ophthalmic spray for mydriasis, and clobetasol propionate ophthalmic suspension for postsurgical inflammation and pain. They are also developing the Optejet® device for pediatric progressive myopia and dry eye treatments, with potential for out-licensing in additional indications.
Investors and interested parties can access the presentation by registering for the conference. Virtual 1x1 meetings with Eyenovia management can be arranged through H.C. Wainwright representatives.
Eyenovia Inc. (NASDAQ: EYEN), un'azienda tecnologica nel settore oftalmico, ha annunciato la sua partecipazione al 4° Convegno Virtuale di Oftalmologia Annuale H.C. Wainwright che si terrà il 15 agosto 2024. La presentazione preregistrata dell'azienda sarà disponibile on-demand a partire dalle 7:00 EDT nel giorno del convegno.
Eyenovia è conosciuta per la commercializzazione di Mydcombi™, uno spray oftalmico per la midriasi, e sospensione oftalmica di clobetasolo propionato per infiammazione e dolore post-chirurgico. L'azienda sta anche sviluppando il dispositivo Optejet® per la miopia progressiva pediatrica e il trattamento dell'occhio secco, con potenziale per concessione in licenza per altre indicazioni.
Gli investitori e le parti interessate possono accedere alla presentazione registrandosi per il convegno. È possibile organizzare incontri virtuali 1x1 con la direzione di Eyenovia tramite i rappresentanti di H.C. Wainwright.
Eyenovia Inc. (NASDAQ: EYEN), una empresa de tecnología oftálmica, anunció su participación en la 4ª Conferencia Virtual Anual de Oftalmología H.C. Wainwright que se llevará a cabo el 15 de agosto de 2024. La presentación pregrabada de la empresa estará disponible bajo demanda a partir de las 7:00 a.m. EDT el día de la conferencia.
Eyenovia es conocida por comercializar Mydcombi™, un spray oftálmico para la midriasis, y una suspensión oftálmica de propionato de clobetasol para la inflamación y el dolor postquirúrgico. También están desarrollando el dispositivo Optejet® para la miopía progresiva pediátrica y el tratamiento del ojo seco, con potencial para licencias adicionales en otras indicaciones.
Los inversores y partes interesadas pueden acceder a la presentación registrándose para la conferencia. Se pueden organizar reuniones virtuales 1x1 con la gerencia de Eyenovia a través de los representantes de H.C. Wainwright.
Eyenovia Inc. (NASDAQ: EYEN), 안과 기술 회사, 가 H.C. Wainwright 제4회 연례 안과 가상 회의에 참여한다고 발표했습니다. 이 회사의 사전 녹화된 발표는 회의 당일 오전 7시 EDT부터 주문형으로 제공될 예정입니다.
Eyenovia는 Mydcombi™, 동공확대용 안과 스프레이와 클로베타솔 프로피온산 나트륨 안과 현탁액을 상업화한 것으로 잘 알려져 있습니다. 이들은 소아 진행성 근시 및 건조안 치료를 위한 Optejet® 장치를 개발 중이며, 추가 적응증에 대한 라이선스 아웃 가능성도 있습니다.
투자자와 관심 있는 당사자는 회의 등록을 통해 발표에 접근할 수 있습니다. H.C. Wainwright 대표를 통해 Eyenovia 경영진과의 가상 1:1 미팅을 조율할 수 있습니다.
Eyenovia Inc. (NASDAQ: EYEN), une entreprise de technologie ophtalmique, a annoncé sa participation à la 4ème Conférence Virtuelle Annuelle d'Ophthalmologie H.C. Wainwright qui se tiendra le 15 août 2024. La présentation préenregistrée de l'entreprise sera disponible à la demande à partir de 7h00 EDT le jour de la conférence.
Eyenovia est connue pour commercialiser Mydcombi™, un spray ophtalmique pour la mydriase, et suspension ophtalmique de propionate de clobétasole pour l'inflammation et la douleur postopératoires. Ils développent également le dispositif Optejet® pour la myopie progressive pédiatrique et le traitement des yeux secs, avec un potentiel de licence dans d'autres indications.
Les investisseurs et les parties intéressées peuvent accéder à la présentation en s'inscrivant pour la conférence. Des réunions virtuelles en tête-à-tête avec la direction d'Eyenovia peuvent être organisées via les représentants de H.C. Wainwright.
Eyenovia Inc. (NASDAQ: EYEN), ein Unternehmen für ophthalmologische Technologie, gab seine Teilnahme an der 4. jährlichen virtuellen Konferenz für Ophthalmologie von H.C. Wainwright am 15. August 2024 bekannt. Die vorab aufgezeichnete Präsentation des Unternehmens wird am Konferenztag ab 7:00 Uhr EDT auf Abruf verfügbar sein.
Eyenovia ist bekannt für die Kommerzialisierung von Mydcombi™, einem ophthalmologischen Spray zur Mydriasis, und Clobetasol-Propionat-Augensuspension zur Behandlung von postoperativer Entzündung und Schmerzen. Das Unternehmen entwickelt auch das Optejet®-Gerät zur Behandlung von progressiver Myopie bei Kindern und trockenen Augen, mit Potenzial für Lizenzvergaben bei weiteren Indikationen.
Investoren und interessierte Parteien können die Präsentation durch Registrierung für die Konferenz abrufen. Virtuelle 1:1-Meetings mit dem Management von Eyenovia können über die Vertreter von H.C. Wainwright arrangiert werden.
- None.
- None.
NEW YORK, Aug. 13, 2024 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), an ophthalmic technology company commercializing Mydcombi™ (tropicamide and phenylephrine hydrochloride ophthalmic spray)
Management’s pre-recorded company presentation can be accessed on-demand beginning at 7:00 am EDT on the day of the conference.
For additional information, or to register for the conference, please click here. To arrange a virtual 1x1 meeting with Eyenovia management, please contact your H.C. Wainwright representative.
PLEASE GO TO MYDCOMBI.COM FOR IMPORTANT SAFETY INFORMATION for MYDCOMBI™ (tropicamide and phenylephrine hydrochloride ophthalmic spray)
PLEASE GO TO CLOBETASOLBID.COM FOR IMPORTANT SAFETY INFORMATION for Clobetasol Proprionate Ophthalmic Suspension
About Eyenovia, Inc.
Eyenovia, Inc. (NASDAQ: EYEN) is a commercial-stage ophthalmic pharmaceutical technology company developing a pipeline of microdose array print therapeutics based on its Optejet platform. Eyenovia is currently focused on the commercialization of Mydcombi (tropicamide+phenylephrine ophthalmic spray) for mydriasis, as well as clobetasol propionate ophthalmic suspension
Eyenovia is also advancing late-stage development of MicroPine for pediatric progressive myopia (partnered with Arctic Vision in China and South Korea).
For more information, visit Eyenovia.com.
The Eyenovia Corporate Information slide deck may be found at ir.eyenovia.com/events-and-presentations.
Eyenovia Contact:
Eyenovia, Inc.
John Gandolfo
Chief Financial Officer
jgandolfo@eyenovia.com
Eyenovia Investor Contact:
Eric Ribner
LifeSci Advisors, LLC
eric@lifesciadvisors.com
(646) 751-4363
Eyenovia Media Contact:
Eyenovia, Inc.
Norbert Lowe
Vice President, Commercial Operations
nlowe@eyenovia.com
FAQ
When is Eyenovia (EYEN) participating in the H.C. Wainwright Ophthalmology Conference?
What time will Eyenovia's (EYEN) presentation be available at the conference?
What products is Eyenovia (EYEN) currently commercializing?
What is Eyenovia (EYEN) developing with its Optejet® device?
How can investors arrange meetings with Eyenovia (EYEN) management during the conference?
